Search results
Showing 1 to 15 of 8073 results
Secukinumab for treating moderate to severe hidradenitis suppurativa [ID4039]
In development [GID-TA11095] Expected publication date: 06 December 2023
In development [GID-QS10162] Expected publication date: 07 December 2023
In development [GID-TA11081] Expected publication date: 13 December 2023
In development [GID-HST10010] Expected publication date: 13 December 2023
In development [GID-TA11448] Expected publication date: 13 December 2023
In development [GID-QS10180] Expected publication date: 14 December 2023
Middle Meningeal Embolisation for Chronic Subdural Haematomas CSDH
In development [GID-IPG10215] Expected publication date: 14 December 2023
In development [GID-NG10186] Expected publication date: 30 October 2024
In development [GID-NG10176] Expected publication date: 06 March 2024
In development [GID-NG10368] Expected publication date: 19 December 2023
Targeted release budesonide for treating IgA nephropathy [ID1434]
In development [GID-TA11028] Expected publication date: 20 December 2023
In development [GID-TA11170] Expected publication date: 20 December 2023
COVID-19 rapid guideline: managing the long-term effects of COVID-19 (NG188)
This guideline covers identifying, assessing and managing the long-term effects of COVID-19, often described as ‘long COVID’. It makes recommendations about care in all healthcare settings for adults, children and young people who have new or ongoing symptoms 4 weeks or more after the start of acute COVID-19. It also includes advice on organising services for long COVID.
View recommendations for NG188Show all sections
Sections for NG188
This guideline covers the management of COVID-19 for babies, children, young people and adults in all care settings. It brings together our existing recommendations on managing COVID-19, and new recommendations on therapeutics, so that healthcare staff and those planning and delivering services can find and use them more easily.
View recommendations for NG191Show all sections
Sections for NG191
COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT) (NG200)
This guideline covers vaccine-induced immune thrombocytopenia and thrombosis (VITT), a syndrome which has been reported in rare cases after COVID-19 vaccination. VITT may also be called vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) or thrombotic thrombocytopenic syndrome (TTS). Because VITT is a new condition, there is limited evidence available to inform clinical management, identification and management of the condition is evolving quickly as the case definition becomes clearer. This guideline was produced to support clinicians to diagnose and manage this newly recognised syndrome.
View recommendations for NG200Show all sections
Sections for NG200